ProCE Banner Activity

SHINE: First-line Ibrutinib + Bendamustine/Rituximab Followed by Rituximab Maintenance in Older Patients With MCL

Slideset Download
Conference Coverage
The addition of ibrutinib to chemoimmunotherapy prolonged median PFS by 2.3 years in older, previously untreated patients with MCL.

Released: June 07, 2022

Expiration: June 06, 2023

Share

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

AbbVie

AstraZeneca

AstraZeneca

Bristol Myers Squibb

Daiichi Sankyo, Inc.

Gilead Sciences, Inc.

GlaxoSmithKline

Jazz Pharmaceuticals, Inc.

Merck Sharp & Dohme Corp.

Novartis Pharmaceuticals Corporation

Seagen

Seagen and Genmab